Federal Hemp Cliff November 12, 2026 — PL 119-37 § 781

Last verified: May 2026

The Statutory Provision

Section 781 of H.R. 5371 (Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026) signed by President Trump on November 12, 2025 caps THC in nationally sold hemp products at 0.4 milligrams per package with a one-year industry adjustment period. Effective date: November 12, 2026 per Congressional Research Service Report IN12620.

The McConnell Provision Origin

The 0.4 mg per package cap is widely attributed to U.S. Senate Republican Leader Mitch McConnell (R-KY), who has been a longtime advocate of hemp legalization (the 2018 Farm Bill that originally legalized hemp federally was largely McConnell-driven) but had become alarmed by the rise of intoxicating hemp-derived products under the 2018 framework. The November 2025 continuing-resolution provision was inserted at McConnell’s direction.

Industry Impact Estimates

The U.S. Hemp Roundtable has stated that the 0.4 mg cap "would wipe out 95% of the industry." A 1-gram vape cartridge typically contains 700-900 mg of THC; a single hemp-derived delta-9 gummy may contain 5-15 mg of THC; a 28-pack of edibles may contain 280 mg total THC. The 0.4 mg per package cap is well below typical product potency.

For Nebraska specifically, Sen. John Cavanaugh (D-Omaha), in his October 2025 complaint against proposed NDA hemp regulations, estimated:

• ~$10 million in annual state sales-tax revenue from hemp businesses.
• ~2,000 Nebraskans employed in hemp retail and related industries.

Federal Industry Estimates

Nationally, the U.S. Hemp Roundtable estimated the U.S. intoxicating hemp market at approximately $28.4 billion in regulated activity in advocacy materials cited during the H.R. 5371 debate. No published authoritative state-level retail-volume figure for Nebraska’s hemp-derived intoxicant market has been identified beyond Cavanaugh’s sales-tax / jobs estimate.

What the 0.4 mg Cap Would Eliminate

• Delta-8 THC vape cartridges: typically 800-1,000 mg per cartridge.
• Delta-10 THC, HHC, THC-O products: similar potency.
• Hemp-derived delta-9 edibles: typically 5-15 mg per gummy, 50-300 mg per package.
• THCA flower: typically 15-25% THCA by weight; a 1-gram pre-roll contains 150-250 mg THCA which converts to delta-9 on heating.
• Concentrate-style hemp products: shatter, wax, rosin marketed as hemp-derived.

What the 0.4 mg Cap Would Permit

• CBD products with sub-threshold THC: tinctures, topicals, capsules.
• Industrial hemp fiber and grain: textiles, animal feed, food ingredients.
• CBG, CBN, CBC products: non-THC cannabinoids.
• Hemp seeds and hemp protein: established food category.

The One-Year Industry Adjustment Period

The November 12, 2025-to-November 12, 2026 adjustment period was negotiated to give hemp businesses time to:

• Sell down existing inventory.
• Pivot to compliant CBD product lines.
• Exit the intoxicating-hemp market or relocate to states with regulated adult-use frameworks.

Industry participants generally regard the one-year window as inadequate for a $28+ billion industry transition, but it is the negotiated outcome.

Federal-Court Challenge Risk

The 0.4 mg cap may be challenged in federal court on grounds including:

• Administrative Procedure Act process challenges.
• Commerce Clause / dormant Commerce Clause arguments around interstate hemp trade.
• Statutory construction arguments around the 2018 Farm Bill’s "all derivatives" language.
• Equal-protection arguments comparing hemp to comparable consumer products.

As of May 2026, no federal court has ruled on the cap. The November 12, 2026 effective date provides incentive for affected industry participants to file challenges before the cap takes effect.

Federal Schedule III Rescheduling Interaction

On April 23, 2026, Acting U.S. Attorney General Todd Blanche issued an order downgrading state-licensed medical cannabis and FDA-approved marijuana products from Schedule I to Schedule III of the federal Controlled Substances Act (91 Fed. Reg. 22714, April 28, 2026). The rescheduling does not directly address hemp, but creates a legal-status divergence: cannabis-as-Schedule-III for state-licensed medical and hemp-as-tightly-capped-under-PL-119-37 for hemp-derived products.

The interaction creates incentive for hemp-derived intoxicant operators to pivot to state-licensed medical-cannabis frameworks where available. In Nebraska, where the state medical-cannabis program has 0 operational dispensaries and no manufacturer or transporter licenses issued as of May 2026, the pivot path is narrow.

Practical Implications for Nebraska

• Retailers: plan for substantial inventory write-downs and product-line transitions before November 12, 2026.
• Consumers: anticipate substantial reduction in legal hemp-derived intoxicant access; product hoarding risks federal violations once the cap takes effect.
• Workers: ~2,000 Nebraska hemp-industry workers face job displacement risk.
• Tax revenue: Nebraska faces loss of ~$10M annual sales-tax revenue from hemp.
• Patient-access: medical-cannabis patients looking for accessible product face the dual constraint of the federal hemp cap and the slow Nebraska medical-program rollout.

Related on this site: AG Hilgers Hemp Enforcement, LB 316 (2025) Hemp-Intoxicant Ban Fai..., Nebraska Hemp Farming Act (LB 657, 2019).